Category: C.R. Bard
A West Virginia judge pushes back the trial date in a legal dispute over C.R. Bard's controversial Avaulta vaginal mesh implants.
Patients in another bellwether trial against C.R. Bard (NYSE:BCR) will have to wait another month to air their grievances in court after a West Virginia judge pushed back their trial date.
C.R. Bard continues to provide medical and surgical supplies to the U.S. Defense Dept. with a $46.3 million extension to its multi-year contract.
Medical device giant C.R. Bard (NYSE:BCR) landed a new $46.3 million contract with the U.S. Defense Dept., extending for a 2nd year a deal to provide the agency with medical supplies.
C.R. Bard says the final module of its pre-market approval application for the Lutonix drug-eluting balloon is in the FDA's hands.
C.R. Bard (NYSE:BCR) said its application for pre-market approval of the Lutonix drug-eluting balloon is complete now that the final module has been filed with the FDA.
C.R. Bard closes its $262 million acquisition of Rochester Medical.
C.R. Bard (NYSE:BCR) closed its $262 million acquisition of Rochester Medical yesterday, giving former Rochester stockholders $20 per share and taking ROCM shares off the NASDAQ exchange.
C.R. Bard can't collect attorney's fees in a dismissed bellwether lawsuit filed over its recalled Avaulta pelvic mesh.
A federal judge this week denied a move by C.R. Bard (NYSE:BCR) to recoup its legal costs from a bellwether lawsuit over its Avaulta pelvic mesh that was dismissed in September.
Six-month data from the Levant-2 trial of C.R. Bard's Lutonix drug-coated balloon comes up with some surprising results.
MASSDEVICE ON CALL — Six-month data from the Levant-2 trial of C.R. Bard's (NYSE:BCR) Lutonix drug-coated balloon for treating femoropopliteal artery disease came as a surprise for those hoping the device will be a breakthrough treatment for peripheral artery disease.
Boston Scientific closes the $275 million acquisition of C.R. Bard's electrophysiology business.